Followers | 9839 |
Posts | 260000 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Thursday, November 01, 2018 5:46:41 PM
Link to Video - click here to watch the technical chart video
Recent ARGX News
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease • GlobeNewswire Inc. • 03/27/2024 06:00:00 AM
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024 • GlobeNewswire Inc. • 03/26/2024 08:00:00 PM
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia • GlobeNewswire Inc. • 03/26/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 11:05:13 AM
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting • GlobeNewswire Inc. • 03/07/2024 09:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 09:04:20 PM
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update • GlobeNewswire Inc. • 02/29/2024 06:00:00 AM
- argenx to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2024 06:00:00 AM
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 11:06:40 AM
- argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy • GlobeNewswire Inc. • 02/20/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/18/2024 11:10:34 AM
- argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis • GlobeNewswire Inc. • 01/18/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 11:06:54 AM
- argenx Highlights 2024 Strategic Priorities • GlobeNewswire Inc. • 01/08/2024 06:00:00 AM
- argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 06:00:00 AM
- Argenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data Talk • Dow Jones News • 12/20/2023 05:37:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 11:00:20 AM
- argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus • GlobeNewswire Inc. • 12/20/2023 06:00:00 AM
- Argenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data Talk • Dow Jones News • 11/28/2023 04:16:00 PM
- Argenx Shares Down After Vyvgart Study Misses Primary Endpoint • Dow Jones News • 11/28/2023 12:03:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 11:01:35 AM
- argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia • GlobeNewswire Inc. • 11/28/2023 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/17/2023 11:01:37 AM
- argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis • GlobeNewswire Inc. • 11/16/2023 12:40:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM